Actively Recruiting
Belimumab to Mobilize Memory B Cells for Improved HLA-Specific Profiling and Delisting in Highly Sensitized Kidney Transplant Candidates
Led by Leiden University Medical Center · Updated on 2026-09-22
25
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether belimumab can improve the detection of circulating HLA-specific memory B cells to help make donor organ allocation safer and more effective for highly sensitized kidney transplant candidates. The study focuses on whether belimumab changes the antigen specificity profile of these memory B cells compared to before treatment, and if using this information can improve donor organ allocation and reduce waiting time for transplantation. Kidney transplantation is limited by antibodies targeting donor HLA molecules, especially for highly sensitized patients who face long wait times and high mortality on dialysis. Current methods to identify low-risk HLA specificities for transplantation are imperfect, and this trial aims to improve risk assessment by assessing memory B cells more accurately. Participants will receive a short course of belimumab, given as 200 mg injections under the skin once weekly for four weeks. Blood samples will be collected before and during treatment to analyze memory B-cell profiles and HLA antibody specificities. Based on these test results, some unacceptable HLA specificities may be adjusted delisted to increase the chance of finding a suitable donor. The trial will also study the effects of belimumab on various immune cells, BAFF levels, and memory B-cell gene expression. Transplant outcomes following delisting will be monitored as well. Participants will be followed for up to two years to observe donor organ allocation and transplantation results. They will provide blood samples at specific times to assess memory B-cell activity, antibody profiles, and other immune markers. The main outcome measured is the probability of organ allocation within 16 weeks. Other outcomes include antibody-mediated rejection rates at one year, graft failure at two years, and detailed immune cell analyses. This study includes safety monitoring and assessments of how belimumab affects immune cells and antibody profiles over time.
CONDITIONS
Brief Title
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized
Research Team
S
Simon Zethof, MD
A
Aiko de Vries, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here